Cited by 122Antimicrobial Peptides and ActivitiesHerpesvirus Infections and TreatmentsAntimicrobial agents and applications

Safety, Formulation and In Vitro Antiviral Activity of the Antimicrobial Peptide Subtilosin Against Herpes Simplex Virus Type 1

Open access
Torres, Nicolás I., Noll, Katia Sutyak, Xu, Shiqi, Li, Ji, Huang, Qingrong, Sinko, Patrick J., Wachsman, Mónica B., Chikindas, Michael L.·2013·Probiotics and Antimicrobial Proteins

Abstract

In the present study the antiviral properties of the bacteriocin subtilosin against Herpes simplex virus type 1 (HSV-1) and the safety and efficacy of a subtilosin-based nanofiber formulation were determined. High concentrations of subtilosin, the cyclical antimicrobial peptide produced by Bacillus amyloliquefaciens, were virucidal against HSV-1. Interestingly, at non-virucidal concentrations, subtilosin inhibited wild type HSV-1 and aciclovir-resistant mutants in a dose-dependent manner. Although the exact antiviral mechanism is not fully understood, time of addition experiments and western blot analysis suggest that subtilosin does not affect viral multiplication steps prior to protein synthesis. Poly(vinyl alcohol) (PVOH)-based subtilosin nanofibers with a width of 278 nm were produced by the electrospinning process. The retained antimicrobial activity of the subtilosin-based fibers was determined via an agar well diffusion assay. The loading capacity of the fibers was 2.4 mg subtilosin/g fiber, and loading efficiency was 31.6%. Furthermore, the nanofibers with and without incorporated subtilosin were shown to be nontoxic to human epidermal tissues using an in vitro human tissue model. Taking together these results subtilosin-based nanofibers should be further studied as a novel alternative method for treatment and/or control of HSV-1 infection.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s12602-012-9123-x

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The bacteriocin subtilosin, produced by Bacillus species, disrupts late infectious stages of both HSV type 1 and HSV type 2.

    “the bacteriocin subtilosin, produced by species of the Bacillus genus, disrupts late infectious stages of both HSV type 1 (Torres et al., 2013) and HSV type 2 (Quintana et al., 2014).”

    From Viral Infections, the Microbiome, and Probiotics (2021) · cites this paper as Torres et al., 2013

  • Some bacteriocins have been observed to display antiviral activity in addition to antibacterial activity.

    “Also, some bacteriocins have been observed to display antiviral activity, in addition to their well-known antibacterial activity (Torres et al., 2013; Quintana et al., 2014).”

    From Viral Infections, the Microbiome, and Probiotics (2021) · cites this paper as Torres et al., 2013

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Torres, N. I., Noll, K. S., Xu, S., Li, J., Huang, Q., Sinko, P. J., Wachsman, M. B., & Chikindas, M. L.
Affiliations
  • Universidad de Buenos Aires (AR)
  • Rutgers, The State University of New Jersey (US)
Corresponding author
Chikindas, Michael L.
Venue
Probiotics and Antimicrobial Proteins
Published
2013-01-13
Volume
5
Issue
1
Pages
26-35
ISSN
  • 1867-1306 (ISSN-L)
  • 1867-1314
OpenAlex
W2050952290
Cited by
122
References
55
Citations by year
2026: 3 · 2025: 6 · 2024: 12 · 2023: 15 · 2022: 13 · 2021: 19 · 2020: 8 · 2019: 6 · 2018: 3 · 2017: 8 · 2016: 8 · 2015: 5 · 2014: 13 · 2013: 2
FWCI
8.58
Type
journal article
Language
en
Open access
Locations
  • Probiotics and Antimicrobial Proteins (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • Rutgers University Community Repository (Rutgers University) (submittedVersion)
Funders
National Institute of Allergy and Infectious Diseases (R01AI084137)
Topics
  • Life Sciences › Immunology and Microbiology › Microbiology › Antimicrobial Peptides and Activities
  • Health Sciences › Medicine › Epidemiology › Herpesvirus Infections and Treatments
  • Physical Sciences › Chemistry › Organic Chemistry › Antimicrobial agents and applications
Keywords
antimicrobial peptides, herpes simplex virus type 1, acyclovir resistance, virucidal activity, nanofibers, polyvinyl alcohol, electrospinning, drug delivery, skin toxicity, Bacillus amyloliquefaciens

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review